Castration Resistant Prostatic Cancer
8
3
3
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
2 terminated out of 8 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC